‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s - BERITAJA

Health Canada has approved a 2nd supplier that could slow the progression of Alzheimer’s disease.

Donanemab, sold by American drugmaker Eli Lilly nether the marque sanction Kisunla, received Health Canada support connected Monday, the institution said successful a property release.

It received support from the U.S. Food and Drug Administration successful 2024.

This is the 2nd disease-slowing supplier for Alzheimer’s that has been approved successful Canada, aft Health Canada approved lecanemab, commercially known arsenic “Leqembi,” successful October 2025.

Donanemab, for illustration lecanamab, targets amyloids — a sticky macromolecule that develops successful the encephalon successful the early stages of Alzheimer’s disease. The buildup of amyloid plaques successful the encephalon whitethorn lead to representation and reasoning issues.

While the supplier is “not a cure,” objective tests indicated the imaginable to slow diminution successful memory, reasoning and regular functioning for immoderate group successful the early stages of Alzheimer’s disease, the Alzheimer’s Society of Canada said.

In objective trials, patients taking Kisunla were capable to extremity curen erstwhile amyloid plaques were cleared, pinch immoderate stopping aft conscionable six months and about half discontinuing curen aft 12 months, Eli Lilly said successful a statement.

Patients successful the early stages of the illness saw the top benefits of the drug, the institution added.

Over 18 months, participants who were little precocious successful their illness showed a 35 per cent slowing of diminution connected the integrated Alzheimer’s Disease Rating Scale (iADRS), which assesses memory, reasoning and regular functioning, the institution said.

For the wide population, donanemab showed a 22 per cent slowing of the disease, the connection added.

The support is “a hopeful milestone for group surviving pinch early Alzheimer’s and their attraction partners,” Alzheimer Society of Canada CEO Christina Scicluna said.

“While not a cure, it shows really acold we’ve travel and why investigation and defense matters. Together pinch our partners crossed Canada, we stay focused connected ensuring group could entree caller treatments alongside the applicable supports they request to navigate what comes next,” Scicluna added successful a statement.

The supplier “provides an important opportunity for early patients to support their independence,” said Dr. Sharon Cohen, neurologist and aesculapian head astatine the Toronto Memory Program.

“Changing the downward trajectory of Alzheimer’s illness is of the utmost importance. Individuals astatine early stages of this illness unrecorded successful their ain homes and lead robust lives but often dread what is to come.”

Health Canada has constricted the usage of the curen for adults who don’t transportation the APOE4 gene.

This familial variant, carried by one-fifth of the world’s population, importantly increases the consequence of dementia.

Side effects of the therapy whitethorn see amyloid-related imaging abnormalities (ARIA). This “may coming arsenic impermanent swelling successful an area aliases areas of the brain,” Eli Lilly said.

Canada’s Drug Agency will now measure whether donanemab should beryllium funded by provincial and territorial supplier plans. The Alzheimer’s Society of Canada said it will advocator for the supplier to beryllium covered by nationalist supplier plans, but cautioned that it could return up to 2 years aft regulatory support for caller medicines to go publically covered.

People pinch backstage security aliases extended wellness benefits often summation entree to treatments much quickly, the nine added.